Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Syros Pharmaceuticals, Inc. - Common Stock (NQ:SYRS)

0.1172 UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Syros Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Unusual volume stocks are being observed in Thursday's session.
Which stocks have an unusual volume on Thursday? 
Via Chartmill
These stocks that are showing activity before the opening bell on Wednesday.
The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
Tuesday's after hours session: top gainers and losers
Discover the top movers in Tuesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
Here are the top movers in Monday's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
Let's take a look at the stocks that are in motion in today's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements. 
Via Chartmill
Which stocks are gapping on Monday?
Traders are paying attention to the gapping stocks in Monday's session. Let's dive into which stocks are experiencing notable gaps. 
Via Chartmill
Monday's pre-market session: top gainers and losers
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. 
Via Chartmill
US Stocks Likely To Open Higher As Wall Street Watches TruTariff Talks: 'March, April, May Tend To Be Solid Months In Post-Election Years,' Says Expert
U.S. stock futures rose on Monday following Friday's advances. Futures of all fourth benchmark indices rose in premarket trading. 
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
After the closing bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
Syros Announces Voluntary Delisting from Nasdaq and SEC Deregistration
From Syros Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
S&P 500 Tops 6,000; Rumble Shares Slide After Q3 Results
 
Via Benzinga
Topics Stocks
Dow Jumps Over 150 Points; CyberArk Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default
Syros Pharmaceuticals' Phase 3 trial of tamibarotene in higher-risk myelodysplastic syndrome did not meet primary endpoints, impacting future trial plans. 
Via Benzinga
US Stocks Mixed; Inflation Rate Increases In October
 
Via Benzinga
Topics Economy
Why Rocket Lab Shares Are Trading Higher By Around 29%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
From Syros Pharmaceuticals
Via Business Wire
Syros Reports Third Quarter 2024 Financial Results and Provides a Business Update
From Syros Pharmaceuticals
Via Business Wire
Syros to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024
From Syros Pharmaceuticals
Via Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Syros Pharmaceuticals, Inc. (SYRS) Investigation: Bronstein, Gewirtz and Grossman, LLC Encourages Shareholders to Seek Compensation for Alleged Wrongdoings
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Syros Pharmaceuticals to Present at Upcoming Medical and Investor Conferences
From Syros Pharmaceuticals
Via Business Wire
SYRS Investors Have Opportunity to Join Syros Pharmaceuticals, Inc. Securities Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Crude Oil Down 2%; Paysafe Shares Surge After Q2 Results
 
Via Benzinga
S&P 500 Gains 1%; Home Depot Earnings Top Views
 
Via Benzinga
Topics Stocks
Nasdaq Surges 200 Points; US Producer Prices Increase 0.1% In July
 
Via Benzinga
Cancer-Focused Syros Pharmaceuticals Stops Mid-Stage Leukemia Combo Therapy Study, Cites Disappointing Unexpected Outcome
Syros Pharmaceuticals announces discontinuing enrollment in the SELECT-AML-1 Phase 2 trial due to the low probability of demonstrating superiority. The trial evaluated tamibarotene with venetoclax and... 
Via Benzinga
Why Is Syros Pharmaceuticals (SYRS) Stock Down 62% Today?
Syros Pharmaceuticals stock is down on Tuesday as SYRS investors react to the company discontinuing enrollment for a clinical trial. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers for Tuesday as we check out all of the hottest news moving shares this morning. 
Via InvestorPlace
Why Rumble Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.